THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0

Citation for published version:

M Tolaney, S, Garrett-Mayer, E, White, J, S. Blinder, V, C. Foster, J, Amiri Kordestani, L, Hwang, S, M. Bliss, J, Rakovitch, E, Perlmutter, J, A. Spears, P, Frank, E, M. Tung, N, D. Elias, A, Cameron, DA, Denduluri, N, F. Best, A, Di Leo, A, Baizer, L, Pearson Butler, L, Schwartz, E, P Winer, E & A. Korde, L 2021, 'Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0', *Journal of Clinical Oncology*. <https://doi.org/10.1200/JCO.20.03613>

Digital Object Identifier (DOI):

[10.1200/JCO.20.03613](https://doi.org/10.1200/JCO.20.03613)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Journal of Clinical Oncology

Publisher Rights Statement:

DOI: 10.1200/JCO.20.03613 Journal of Clinical Oncology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Sara M. Tolane, MD, MPH^{1,2}; Elizabeth Garrett-Mayer, PhD³; Julia White, MD⁴; Victoria S. Blinder, MD⁵; Jared C. Foster, PhD⁶; Laleh Amiri-Kordestani, MD⁷; E. Shelley Hwang, MD, MPH⁸; Judith M. Bliss, MSc⁹; Eileen Rakovitch, MD¹⁰; Jane Perlmutter, PhD, MBA¹¹; Patricia A. Spears, BS¹²; Elizabeth Frank, EdM¹; Nadine M. Tung, MD¹³; Anthony D. Elias, MD¹⁴; David Cameron, MD¹⁵; Neelima Denduluri, MD¹⁶; Ana F. Best, PhD⁶; Angelo DiLeo, MD, PhD¹⁷; Lawrence Baizer, PhD¹⁸; Lynn Pearson Butler, MS¹⁹; Elena Schwartz, PhD¹⁸; Eric P. Winer, MD^{1,2}; and Larissa A. Korde, MD²⁰

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvements in outcomes, a panel of experts reviewed the STEEP criteria to determine whether modifications are needed.

METHODS We conducted systematic searches of [ClinicalTrials.gov](https://clinicaltrials.gov) for adjuvant systemic and local-regional therapy trials for breast cancer to investigate if the primary end points reported met STEEP criteria. On the basis of common STEEP deviations, we performed a series of simulations to evaluate the effect of excluding nonbreast cancer deaths and new nonbreast primary cancers from the invasive disease-free survival end point.

RESULTS Among 11 phase III breast cancer trials with primary efficacy end points, three had primary end points that followed STEEP criteria, four used STEEP definitions but not the corresponding end point names, and four used end points that were not included in the original STEEP manuscript. Simulation modeling demonstrated that inclusion of second nonbreast primary cancer can increase the probability of incorrect inferences, can decrease power to detect clinically relevant efficacy effects, and may mask differences in recurrence rates, especially when recurrence rates are low.

CONCLUSION We recommend an additional end point, invasive breast cancer-free survival, which includes all invasive disease-free survival events except second nonbreast primary cancers. This end point should be considered for trials in which the toxicities of agents are well-known and where the risk of second primary cancer is small. Additionally, we provide end point recommendations for local therapy trials, low-risk populations, noninferiority trials, and trials incorporating patient-reported outcomes.

J Clin Oncol 00. © 2021 by American Society of Clinical Oncology

INTRODUCTION

In 2007, a group of breast cancer experts from the National Cancer Institute (NCI) and the National Clinical Trials Network proposed standardized definitions for efficacy end points in adjuvant breast cancer therapeutic trials, widely known as the Standardized Definitions for Efficacy End Points (STEEP). Their proposed end point definitions are summarized in [Table 1](#).¹ The STEEP criteria have since been used and referred to broadly in breast cancer clinical trials. The expert panel that proposed the original STEEP criteria endorsed invasive disease-free survival (IDFS) as a less ambiguous end point than disease-free survival (DFS), which had historically varied significantly across trials in terms of the events included. The definition for IDFS included invasive local, regional, and distant recurrences; contralateral breast cancer; second nonbreast primary cancer; and death from any cause. IDFS was meant to specifically exclude in situ cancer events (ipsilateral and/or contralateral ductal carcinoma in situ [DCIS], lobular

carcinoma in situ [not deemed a preinvasive cancer], and all in situ cancers of nonbreast sites). A separate end point termed IDFS-DCIS was proposed for trials in which inclusion of DCIS events was deemed appropriate.¹

Breast cancer clinical trials and treatments have evolved substantially since the STEEP criteria were established. Advances include improved sensitivity of diagnostic imaging, development of multiple immunohistochemistry markers that distinguish disease origin, and clinical acknowledgment of the need for pathologic confirmation of recurrence. In addition, improvements in breast cancer management have decreased the risk of recurrence, leading to a relatively higher likelihood of death from nonbreast cancer causes in adjuvant trial participants.^{2,3} Moreover, because of the improvements in managing treatment-related toxicities and a commitment to enrolling a group of patients more representative of the actual affected population, patients enrolled in clinical trials increasingly include older patients. These patients have a higher risk of dying from causes

ASSOCIATED CONTENT

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on April 9, 2021 and published at ascopubs.org/journal/jco on May 18, 2021; DOI <https://doi.org/10.1200/JCO.20.03613>

CONTEXT

Key Objective

Given the evolution of breast cancer clinical trials and improvements in outcomes, are modifications to the STEEP criteria needed?

Knowledge Generated

An additional endpoint, invasive breast cancer-free survival, which includes all invasive disease-free survival events except second nonbreast primary cancers, can be considered for trials in which the toxicities are well known and where risk of second primary cancer is small. Additional end points for local therapy trials, low-risk populations, noninferiority trials, and trials incorporating patient-reported outcomes are also included.

Relevance

The choice of a primary end point is critical for detecting a treatment effect and including events that have similar rates in the treatment groups may dilute treatment differences and can increase the likelihood of a false inference of noninferiority.

unrelated to their breast cancer or treatment. This evolution in breast cancer treatment and outcomes led the NCI and National Clinical Trials Network Breast Cancer Steering Committee to convene an international group of experts to reassess the STEEP criteria and to determine whether modifications were needed. The panel focused on end points for the adjuvant setting.

STEEP Adherence

We assessed utilization of STEEP criteria in phase III adjuvant trials published after January 1, 2008 (after the original STEEP publication) with a completion date for the primary analysis before January 1, 2020. Deviations from STEEP definitions were discussed by the panel and these deviations and discussions were used to inform the proposed updated recommendations. The review was conducted in ClinicalTrials.gov using the following search criteria:

1. Breast cancer (for Condition);
2. Adjuvant (for Other terms);
3. Active, not recruiting, Suspended, Terminated, or Completed (for Status); and
4. Phase 3 (for Study phase).

Of the resulting 83 trials, nonadjuvant trials, those without primary efficacy end points, and those without a full manuscript publication (because of inability to fully assess end point definition) were excluded. The search yielded 11 adjuvant phase III breast cancer trials with primary efficacy end points (Table 2).⁴⁻¹⁴ Of these, three had primary end points that fully complied with the STEEP criteria, four used STEEP definitions but not the corresponding end point names (eg, used STEEP IDFS but called it DFS), and four used definitions not included in the original STEEP manuscript.

Since the initial search did not produce a comprehensive list, we broadened our search to include all phase III adjuvant trials that had a primary efficacy end point, listed

results, and had a primary completion date between January 1, 2010 and January 1, 2020 (Data Supplement, online only).^{4-6,9,12,15-37} The resulting list is still not comprehensive but adequately reflects variability in end points across trials and deviations from end point definitions. Trials were divided into five categories: superiority, local therapy, endocrine, low-risk population, and noninferiority trials.

Superiority Trials

Most superiority trials either used or referenced a STEEP definition and stated which events were not included (Data Supplement). In trials that deviated from STEEP, the most common deviation was exclusion of second nonbreast primary cancers. While developing the original STEEP guidelines, inclusion of second nonbreast primary cancer in the IDFS definition was strongly debated, given the potential disadvantage of including events that are not related to the cancer or the treatment being studied, which might dilute the efficacy effect. However, IDFS can identify events that may be related to treatment, such as uterine cancer from tamoxifen. Additionally, it avoids the potential problem of missing distant recurrences that were erroneously diagnosed as new primary cancers. Because second cancers are usually serious, often affect overall survival (OS), and might not be distinguishable from breast cancer or treatment-related events, the original STEEP panel favored including them in the IDFS definition. The three trials in our review that excluded second nonbreast primary cancers all examined the addition of new targeted therapies to standard chemotherapy and trastuzumab-based therapy for early-stage breast cancer,^{5,6,9} and all three led to US Food and Drug Administration (FDA) approval of the agents in early-stage breast cancer.

Modeling the limitations of IDFS. Common wisdom suggests that for time-to-event end points, such as IDFS or recurrence-free interval (RFI), more events means more power. However, having more events does not necessarily translate to increased power and may decrease power

TABLE 1. Standardized Definitions for Breast Cancer Clinical Trial End Points in the Adjuvant Setting and New Definitions Proposed for STEEP 2.0

Adjuvant Trials										
End Point	Invasive IBTR	Local-Regional Invasive Recurrence	Distant Recurrence ^a	Death From Breast Cancer	Death From Non-Breast Cancer Cause	Death From Unknown Cause	Invasive Contralateral Breast Cancer ^b	Ipsilateral DCIS	Contralateral DCIS	Second Primary Invasive Cancer (nonbreast) ^c
OS				X	X	X				
DFS-DCIS	X	X	X	X	X	X	X	X	X	X
IDFS	X	X	X	X	X	X	X			X
DDFS			X	X	X	X				X
DRFS			X	X	X	X				
RFS	X	X	X	X	X	X				
RFI ^d	X	X	X	X						
Breast cancer–free interval	X	X	X	X			X	X	X	
Distant RFI			X	X						
IBCFS	X	X	X	X	X	X	X			
Local-Regional Therapy Trials										
End Point	Invasive Ipsilateral Tumor Recurrence in Breast or Chest Wall ^e			Ipsilateral DCIS	Nodal Recurrence in Ipsilateral Axilla, SCL, or Internal Mammary Regions			Contralateral Invasive Cancer or DCIS		
LRR	X			X	X					
IBR	X			X						
IBR-invasive	X									
IBR-DCIS				X						
Regional nodal recurrence					X					
New contralateral primary								X		

NOTE. Lobular carcinoma in situ is not included as an event in these definitions as it is not generally considered to be a direct precursor of breast cancer. New definitions are shown in bold: (1) adjuvant trial end points were proposed in original STEEP, except for IBCFS; (2) local-regional therapy trial end points were not proposed in the original STEEP. Adapted from original STEEP paper.¹

Abbreviations: DCIS, ductal carcinoma in situ; DDFS, distant disease-free survival; DFS-DCIS, disease-free survival-ductal carcinoma in situ; DRFS, distant relapse-free survival; IBCFS, invasive breast cancer-free survival; IBR, ipsilateral breast recurrence; IBR-DCIS, ipsilateral breast recurrence-ductal carcinoma in situ; IBTR, ipsilateral breast tumor recurrence; IDFS, invasive disease-free survival; LRR, locoregional recurrence; OS, overall survival; RFI, recurrence-free interval; RFS, recurrence-free survival; SCL, supraclavicular; STEEP, Standardized Definitions for Efficacy End Points.

^aSite of first metastasis should be reported using the appropriate common data element term.

^bThe term contralateral invasive breast cancer is preferred to second primary breast cancer as it is less ambiguous. Ipsilateral invasive breast cancers are presumed to be a recurrence.

^cSecond nonbreast primary cancers should not include squamous or basal cell skin cancers or new in situ carcinomas of any site.

^dInterval signifies time from random assignment or registration to event.

^eCan include in-breast recurrence or new primary after lumpectomy, chest wall recurrence after mastectomy, or both, depending on the patient population specified in eligibility criteria.

when some events included in the outcome have the same rates in the two arms of the study and others have different rates. To understand the potential impact of including second nonbreast primary cancer diagnoses on the primary end point that may or may not be related to disease or treatment, simulations were performed that assumed a two-arm study, comparing a standard-of-care (SOC) therapy with an experimental therapy. Traditional IDFS was

compared with IDFS with second nonbreast primary cancers excluded; we termed this modified end point invasive breast cancer-free survival (IBCFS). [Figure 1](#) demonstrates a superiority trial that aims to detect a 95% 3-year IBCFS in the experimental arm versus 92% in the SOC arm (ie, detection of a hazard ratio [HR] of 0.615 [red points]). This trial has approximately 90% power with a sample size of 2,000 patients with a two-sided alpha of .05, assuming 3

TABLE 2. Trials Identified in the Review of STEEP 1.0 Adherence

Trial	Type of Intervention	Study Arms	Primary End Point	Used STEEP Definition?	Referenced STEEP 1.0?
D-CARE ⁴	Bone-targeted treatment	SOC ± denosumab	BMFS	No	No
APHINITY ⁵	Targeted therapy	Chemotherapy + trastuzumab ± pertuzumab	IDFS ^a	No	Yes
KATHERINE ⁶	Targeted therapy	Trastuzumab v T-DM1	IDFS ^a	No	Yes
PRESENT ⁷	Vaccine	GM-CSF ± NP-S	Either DFS-DCIS or IDFS	Yes ^b	No
NSABP B47 ⁸	Targeted therapy	Chemotherapy ± trastuzumab	IDFS	Yes	No
ExteNET ⁹	Targeted therapy	Trastuzumab ± neratinib	IDFS ^a	No	No
PlanB ¹⁰	Chemotherapy	Epirubicin/cyclophosphamide/docetaxel (four cycles) v docetaxel/cyclophosphamide (six cycles)	IDFS (but they called it DFS)	Yes ^b	No
SOLD ¹¹	Targeted therapy (reduced duration)	Docetaxel + trastuzumab (9 weeks) → FEC v Docetaxel + trastuzumab (9 weeks) → FEC + trastuzumab (to complete 1 year)	IDFS (but they called it DFS)	Yes ^b	No
TITAN ¹²	Chemotherapy	Doxorubicin + cyclophosphamide → ixabepilone v Doxorubicin + cyclophosphamide → paclitaxel	RFS	No ^b	No
DBC07-READ ¹³	Chemotherapy	Cyclophosphamide + docetaxel ± epirubicin	IDFS	Yes	No
NSABP B-46-I ¹⁴	Targeted therapy	TC6, TAC6, or TC6 plus bevacizumab	IDFS	Yes	No

Abbreviations: BMFS, bone metastasis-free survival; DFS, disease-free survival; DFS-DCIS, disease-free survival-ductal carcinoma in situ; FEC, fluorouracil, epirubicin, and cyclophosphamide; GM-CSF, granulocyte-macrophage colony-stimulating factor; IDFS, invasive disease-free survival; NP-S, nelipepimut-S; RFS, recurrence-free survival; SOC, standard of care; STEEP, Standardized Definitions for Efficacy End Points; TAC6, docetaxel + doxorubicin + cyclophosphamide ×6 cycles; TC6, docetaxel + cyclophosphamide ×6 cycles; T-DM1, trastuzumab emtansine.

^aIDFS indicates IDFS with second nonbreast primary cancer excluded.

^bUsed the STEEP definition, but not the corresponding STEEP end point name.

years of enrollment and 3 years of follow-up after the last patient is enrolled.

To investigate the impact of second nonbreast cancers on the IDFS end point, an annual rate of 1% was assumed for this event in the SOC and 0.5%, 1%, and 2% in the experimental arms, respectively (Figs 1A-1C). Figure 1 shows that the estimated HR for IBCFS is insensitive to these events, even when the rates vary between the SOC and experimental arms because of censoring event times for these nonrecurrence events (ie, the HRs for the two scenarios are essentially the same for all three panels of Fig 1 for IBCFS). However, the HR for IDFS varies for different rates of second primary diagnosis. Even when the rate of second nonbreast cancers is the same in the SOC and experimental arms (1%; Fig 1B), the HR is higher (HR = 0.71) and power is lower (81%) compared with using IBCFS as the primary end point. Thus, adding events to an end point will not necessarily increase the power: if the event added has the same rate in the two treatment groups, the inclusion of the event will dilute the treatment effect, increasing the chance of a false-negative result. When the rate in the experimental arm is higher (2%) than in the SOC arm (1%), the power drops to 5% and the HR becomes 0.99 (Fig 1C). Conversely, when the rate in the

experimental arm is lower (0.5%), the power increases and the HR moves further from 1 (power = 99%; HR = 0.58; Fig 1A). Thus, if the event rate of second nonbreast cancers differs in the two treatment groups (possibly because of chance imbalances), the HR and the power will both be affected, and IDFS will favor the arm with the lower rate.

This highlights the challenge of incorporating multiple events in the same end point: it is not possible to distinguish which events are driving the differences between arms. Figure 1 reveals that inclusion (or exclusion) of events from the primary end point can have a dramatic effect on inferences in the trial, depending on the relative rates of these events. When there is no difference in the event rates of second nonbreast cancers between the SOC and experimental arms, including them will dilute the observed efficacy effect of interest and decrease the power. However, excluding them could mask unanticipated toxicity effects, and if excluded, toxicity effects should be considered as a separate (secondary) end point to ensure differences in treatment arms are identified if they exist (see the Data Supplement regarding further implications on sample size).

Also shown in Figure 1 are analogous results to those described above; but when a superiority trial assumes a 3-year IBCFS of 72% versus 75% (blue points), the effects on

FIG 1. Comparison of IDFS versus IBCFS in the superiority design setting. Assumed new non-BC second primary cancer rate in the SOC arm is 0.01 annually and in the Exptl arm is (A) 0.005 (lower rate), (B) 0.01 (same rate), or (C) 0.02 (higher rate) annually. Two-sided α of .05 and 3 years of follow-up. Data simulated under the two models. Red: hypothesis of 92% 3-year IBCFS (SOC) versus 95% (Exptl) (HR = 0.615); sample size of 1,000 per arm. Blue: hypothesis of 72% 3-year IDFS without new non-BC second primary cancer events (SOC) versus 75% (Exptl) (HR = 0.876); sample size of 3,341 per arm. BC, breast cancer; Dx, diagnosis; Exptl, experimental; HR, hazard ratio; IBCFS, invasive breast cancer-free survival; IDFS, invasive disease-free survival; SOC, standard of care.

power and the estimated HRs trend in the same direction as those in the previous example. However, the effects of varying rates of second nonbreast cancers on the HR and power are substantially lower, demonstrated by the much smaller differences in IDFS versus IBCFS for the blue versus the red points. Thus, trials that have low event rates are particularly sensitive to the number and types of events that are included in the primary end point.

Figure 2 provides analogous results to Figure 1 in a non-inferiority de-escalation setting, demonstrating that an event with a low rate can have a substantial effect on inferences when the rate of recurrence is low, leading to an increased chance of falsely inferring noninferiority when, in fact, inferior effects of treatment have been masked by inclusion of unrelated events (Data Supplement).

On the basis of our review and these results, IBCFS, which includes all events in IDFS except second nonbreast cancers,

is proposed (Table 1). IBCFS has already been used in numerous trials that have led to FDA approval of drugs in the adjuvant setting and may be preferred over IDFS in superiority trials if the intervention being assessed has been well-studied in the population likely to be enrolled in the trial and is known not to cause second nonbreast cancers. Second nonbreast primary cancers should still be ascertained, and standard IDFS should be reported as a secondary outcome. The IBCFS end point should only be used in trials in which the events that contribute to the primary and secondary outcomes can be adequately adjudicated. If a trial is conducted in lower-resource settings where imaging and other diagnostics cannot distinguish metastases from second nonbreast cancers, this end point is not optimal. Additionally, it is important that long-term follow-up be conducted and reported to better understand late events and toxicities and that all STEEP end points be reported so that a better understanding of events and end points can be ascertained.

FIG 2. Comparison of IDFS versus IBCFS in the noninferiority, de-escalation design setting. Assumed new non-BC second primary cancer rate in the SOC arm is 0.01 annually and in the Exptl arm is (A) 0.005 (lower rate) or (B) 0.01 (same rate) annually. Five years of follow-up; inference on the basis of upper limit of 90% CI for HR. Data simulated under the two models. Red: hypothesis of 95% 5-year IBCFS (SOC) versus 93.5% (Exptl) (HR = 1.31); sample size of 1,000 per arm. Blue: hypothesis of 75% 5-year IDFS without new non-BC second primary cancer events (SOC) versus 73.5% (Exptl) (HR = 1.07); sample size of 2,750 per arm. BC, breast cancer; Dx, diagnosis; Exptl, experimental; HR, hazard ratio; IBCFS, invasive breast cancer-free survival; IDFS, invasive disease-free survival; SOC, standard of care.

Local Therapy Trials

To understand the typical end points used in adjuvant local therapy trials, we searched [ClinicalTrials.gov](https://clinicaltrials.gov) for local therapy trials using the following search criteria:

1. Breast cancer (for Condition);
2. Adjuvant (for Other terms);
3. Active, not recruiting, Suspended, Terminated, or Completed (for Status); and
4. Phase 3 (for Study phase).

Since these types of trials and end points were not discussed in the original manuscript, we extended this search to trials that started on or after January 1, 1999 and had primary completion on or before January 1, 2020. Of the 181 trials identified, only three were local therapy trials: RTOG-9804,³⁸ ACOSOG-Z0011,³⁹ and APBI-IMRT-Florence.⁴⁰ The primary end points were ipsilateral breast tumor recurrence (IBTR), 10-year OS, and 5-year IBTR, respectively (Table 3).³⁸⁻⁴⁰ As this search did not yield a

comprehensive list, we reviewed a wider collection of adjuvant phase III local therapy trials in breast cancer (Data Supplement).^{38,41-52}

Surgical and radiotherapy trials. As improvements in systemic therapy have reduced the risk of distant recurrence, many recent trials have focused on optimizing local therapy. These include randomized trials of whole-breast radiotherapy (RT) versus observation following breast-conserving therapy,^{38,49} whole-breast versus partial-breast RT,^{42,46,48} and local excision versus observation^{41,43-45,47,50,51} (Data Supplement). For these trials, IBTR was the predominant primary end point. The composite end point IBTR does not allow discrimination of histologic type (invasive or DCIS) or location of in-breast recurrence. We, therefore, recommend alternative locoregional end points that differentiate these events (Table 1). These end points will provide more informative data on cancer progression and therapeutic effect (eg, comparison of in-field versus out-of-field recurrences).

TABLE 3. Local Therapy Trials Identified in [ClinicalTrials.gov](https://clinicaltrials.gov)

Trial	Type of Intervention	Study Arms	Primary End Point
RTOG-9804 ³⁸	Radiation	Optional tamoxifen ± whole-breast RT	IBTR
ACOSOG-Z0011 ³⁹	ALND	Whole-breast RT ± ALND	10-Year OS
APBI-IMRT-Florence ⁴⁰	Radiation	Whole-breast RT v accelerated partial-breast RT	5-Year IBTR

Abbreviations: ALND, axillary lymph node dissection; IBTR, ipsilateral breast tumor recurrence; OS, overall survival; RT, radiation therapy.

We recommend a new composite end point, ipsilateral breast recurrence (IBR), defined as the development of a subsequent invasive breast cancer (either a recurrent cancer or a new primary) or DCIS in the ipsilateral breast or on the chest wall (Table 1). The terms IBR-invasive and IBR-DCIS can be used in trials where distinguishing invasive from DCIS local recurrences is critical. The quadrant location of both the primary and recurrence should be recorded if feasible, to distinguish between recurrences within or outside of the tumor bed, or outside of the radiated field. Contralateral breast tumor recurrence, including invasive cancer and DCIS, should continue to be recorded as a separate locoregional end point, and a competing risks approach for analysis should be considered.

Regional nodal treatment. Randomized trials of regional nodal treatment include trials of nodal RT versus none and trials of axillary nodal dissection versus nodal RT, either in the adjuvant setting or following neoadjuvant treatment. Although some reported trials used end points contained within STEEP 1.0, the panel recommends including an additional end point: regional nodal recurrence, defined as tumor recurrence in lymph nodes in the ipsilateral axilla, supraclavicular fossa, or internal mammary region. We also recommend explicitly indicating the location of the nodal recurrence where possible. We propose the inclusive end point locoregional recurrence to include ipsilateral breast or chest wall recurrence of invasive cancer or DCIS and any ipsilateral recurrence in these nodal groups. These end points are particularly relevant for trials of de-escalation of axillary nodal surgery.

Endocrine Therapy Trials

Endocrine therapy trials were given special consideration in the original guidelines, which noted inconsistencies in the definition of DFS among adjuvant trials comparing aromatase inhibitors with tamoxifen. Since the incidence of contralateral breast primaries is altered by endocrine therapy, it is important to include these in the primary end point to adequately characterize the benefits of the treatment. However, these events may not be as important as distant recurrences to different groups of patients. For example, those who have had bilateral mastectomies are generally not considered to be at sufficient risk of a contralateral primary breast cancer for that benefit to justify therapy. Patients who experience symptomatic toxicities may decline to continue therapy if it does not prevent a distant recurrence. Thus, as was noted in the original

guidelines,¹ publications should include a table detailing the prevalence of event type (ipsilateral, contralateral, and distant) by study arm. This allows for clinicians to individualize the discussion of risks and benefits of the intervention for a patient's clinical situation and treatment goals.

Low-Risk Populations

When the anticipated event rate in a treated population is low, a randomized trial may not be feasible given the large sample size that would be required to demonstrate a treatment effect. If historical data exist for the anticipated event rate with the standard of care, a single-arm trial that identifies a clinically acceptable event rate with a new treatment may be acceptable.

Two recent examples of single-arm trial designs that influenced the standard of care for early-stage breast cancer are the low-risk arm of TAILORx⁵³ and APT.^{54,55} In TAILORx, on the basis of robust retrospective data that failed to demonstrate a benefit for adjuvant chemotherapy in patients with low Oncotype Dx recurrence score,⁵⁶ patients with a recurrence score of 0-10 were treated with endocrine therapy alone. These patients had a 5-year IDFS of 93.8% (95% CI, 92.4 to 94.9) and RFI of 99.3% (95% CI, 98.7 to 99.6),⁵³ confirming endocrine therapy alone as the preferred treatment and the dominance of non-breast cancer events in such a population.

Similarly, the APT trial prospectively assessed whether a systemic therapy regimen (paclitaxel and trastuzumab) was associated with a clinically acceptable event rate in patients with small, node-negative human epidermal growth factor receptor 2-positive breast cancers. This trial demonstrated a 7-year IDFS of 93% (95% CI, 90.4 to 96.2) and a 7-year RFI of 97.5% (95% CI, 95.9 to 99.1).^{54,55} Although the APT study cannot conclude that treatment with paclitaxel and trastuzumab is better than no therapy, the low event rate suggests that escalating therapy by using more intensive regimens, such as those administered in the pivotal adjuvant studies, is unlikely to produce better outcomes.

When choosing an end point for a trial in patients at a relatively low risk of distant or local recurrence, it is important to acknowledge that IDFS captures events such as new contralateral primary breast cancers and deaths from other causes that do not reflect a recurrence of the initial breast cancer. With long follow-up, the frequency of these events increases, and their occurrence may dilute the

effect of treatment on the end point. RFI, which includes invasive locoregional and distant recurrences and deaths as a result of breast cancer (but not contralateral breast cancer, second nonbreast primary cancers, and nonbreast cancer death), may better describe the relevant event rate in this patient population and should be considered in these settings. However, we acknowledge that in older patient populations, a comparison of all-cause mortality may also be relevant, to provide context for cancer-specific mortality. To evaluate the impact of including nonbreast cancer deaths in low-risk patient populations, simulations were performed similar to those shown in Figure 1 (Data Supplement).

If RFI is used as the primary end point, IDFS should still be presented as a secondary end point since it has the advantage of potentially uncovering previously unidentified treatment toxicities.

Noninferiority Trials

Noninferiority trials are designed to demonstrate that an alternative treatment is not less effective than a standard treatment by a prespecified amount (noninferiority margin). This trial design has been increasingly used to assess treatment de-escalation, either by using a new, less toxic agent or by assessing a shorter duration of therapy or omission of a treatment modality.

Critical to the design of noninferiority trials is the identification of a clinically acceptable noninferiority margin. Noninferiority trials should include careful adverse event reporting, especially if outcomes are similar in trial arms, as the adverse event profile may be essential for making treatment decisions. Historically, cross-trial comparison has been complicated by the use of different end point definitions and noninferiority thresholds in different trials conducted in similar populations. The MINDACT⁵⁷ trial and the randomized portion of TAILORx²² both assessed whether chemotherapy could be omitted in patients defined by a genomic profile; however, the studies used different primary end points (5-year IDFS in TAILORx; distant metastasis-free survival in MINDACT) and different thresholds. Both trials achieved results well within the specified noninferiority thresholds, but it is difficult to compare results since different end points and noninferiority thresholds were used (Table 4).

Modeling the limitations of IDFS. As demonstrated in Figure 2 and described above, events with low rates can affect estimation of HRs and the effects are more dramatic in low-risk populations, leading to increased chance of falsely concluding noninferiority when unrelated events are included in end point definitions. Noninferiority trials are particularly relevant in low-risk populations as the avoidance of toxicity is more important when the expected risk of recurrence is low. Thus, as above, consideration of IBCFS or RFI as the primary end point may be warranted so that

events captured are a true reflection of therapy administered. Comparisons of RFI and RFS in the noninferiority, de-escalation design setting are shown in the Data Supplement. The results are similar to those for comparing IDFS and IBCFS.

Patient-Reported Outcomes as a Trial End Point

An important goal in a randomized controlled trial of adjuvant therapy is to provide clinically relevant information that can inform shared decision making. Including patient-reported outcome (PRO) assessments in clinical trials can provide information about a patient's health that is important in discussions between patients and their clinicians. Validated PRO assessments that can help inform decision making should be included whenever possible. For example, PRO-Common Terminology Criteria for Adverse Events can be used to assess symptomatic adverse events to measure safety and tolerability from patients' perspectives.⁵⁸ Furthermore, if PROs are critical to the overall trial objectives, the study should be designed to accommodate them. For example, a PRO may be classified as a co-primary rather than secondary end point, with the type I error divided between primary end points. Importantly, PRO results should be reported concurrently with efficacy results so that both sets of results may be interpreted together to provide a balanced evaluation of advantages and disadvantages to each arm of a trial. This is particularly vital in noninferiority studies where patients and their clinicians will need to weigh the possible loss of efficacy against the potential gain in quality of life.

Regulatory Considerations

The primary end point of an oncology clinical trial can serve different regulatory purposes (eg, a clinical end point that represents clinical benefit for regular or traditional approval, such as OS; a surrogate end point to support traditional approval, such as IDFS; or a surrogate end point to support an accelerated approval, such as overall response rate). The determination is generally based on the specific disease and is dependent on factors such as effect size, available therapy, disease setting, and the risk-benefit relationship. Historically, the use of IDFS as the primary end point in adjuvant breast cancer trials has conferred advantages, but it is also subject to important disadvantages as discussed above. Furthermore, the definition of IDFS has varied among trials, and it includes nonbreast cancer deaths and second nonbreast primary cancers. The FDA has released a guidance for sponsors to select appropriate end points for oncology trials that will support marketing applications.⁵⁹ It is recommended that sponsors meet with the FDA before submitting protocols intended to support a new drug or biologics license marketing application. The FDA has advised that they will ensure that these meetings include a multidisciplinary team of oncologists, statisticians, clinical pharmacologists, and external expert consultants as needed. Sponsors can request a special

TABLE 4. Important Considerations by Type of Trial

Trial Type	Considerations
Superiority trials	IBCFS may be preferred over IDFS if the intervention being assessed has been well-studied in the population likely to be enrolled in the trial and is known not to cause second nonbreast cancers Second nonbreast primary cancers should still be ascertained, and standard IDFS should be reported as a secondary outcome The IBCFS end point should only be used in trials in which the events that contribute to the primary and secondary outcomes can be adequately adjudicated
Endocrine therapy trials	DFS is a reasonable end point, but it is critical to provide breakdown of the prevalence of each type of event (ipsilateral, contralateral, and distant) by study arm
Low-risk trials	RFI may better describe the relevant event rate in this patient population and should be considered, and IDFS should also be reported
Noninferiority trials	Consideration of IBCFS or RFI as the primary end point may be warranted so that the events captured are a true reflection of the therapy administered IDFS should also be reported
Breast surgery and radiation therapy trials	Consider IBR as the primary end point (see Table 1 for local-regional therapy end points)

Abbreviations: DFS, disease-free survival; IBCFS, invasive breast cancer–free survival; IBR, ipsilateral breast recurrence; IDFS, invasive disease-free survival; RFI, recurrence-free interval.

protocol assessment that provides confirmation of the acceptability of study design and end points to support drug marketing applications.

SUMMARY

The original STEEP criteria were established for adjuvant breast cancer trials, recognizing that it is critical to select the appropriate multievent end point to describe treatment benefits and risks and to allow for cross-trial comparisons. This article addresses end points for phase III trials of either adjuvant or local-regional therapy trials for patients with breast cancer. We did not consider end point selection for trials assessing neoadjuvant breast cancer therapies, or adjuvant therapy after neoadjuvant therapy, which were reviewed by Fumigalli et al⁶⁰ in an effort led by the Breast International Group and the NCI-sponsored North American Breast Cancer Group. However, we think our proposed revision of adjuvant trial end points could be applicable to longer-term end points of such studies.

The simulations described in this article illustrate that the choice of primary end point is critical for detecting a treatment effect and raise several important points to consider:

1. When choosing an end point that includes multiple events, it is often difficult to identify which events are driving the estimated HR. Even if the HR is close to 1, it cannot be inferred that the treatments have similar efficacy and toxicity effects—in fact, these could be offsetting each other, with one treatment having higher toxicity yet lower efficacy than the other.
2. Including events that have the same or similar rates in treatment groups will compromise power and may dilute other treatment differences in superiority trials.

In noninferiority trials, it can increase the likelihood of false inference of noninferiority.

3. When events of interest are relatively rare, the impact of including events that are unaffected by treatment is more substantial. However, in situations when events are rare, it is risky to assume, rather than test, whether or not the events may be treatment related.

When agents being studied have well-known toxicity profiles and have been shown not to increase the risk of death, occurrence of second nonbreast primary cancers, or other serious adverse events, IBCFS and RFI should be considered as alternatives to IDFS. When choosing an appropriate end point, characteristics of the population being studied, including comorbidities and competing risks, should be considered. Regardless of the primary end point, data pertaining to both IDFS and IBCFS (or other relevant complementary end points) should be captured and reported in study results, with clear rationale of which end point was a priori selected as the primary end point. RFI, which includes invasive locoregional and distant recurrences and breast cancer–related deaths, may better describe the relevant event rate in low-risk patient populations and thus should be used in these settings. Inclusion of at least one other STEEP end point in a secondary objective is essential to understand how treatments affect different end points. Additionally, it is important for trials to have long-term follow-up not only to understand efficacy over time but also to evaluate late toxicities. Finally, inclusion of appropriately measured and powered PROs, and timely reporting of their results, ideally concurrently with the efficacy end points, is important to ensuring that study results may be used to best inform clinical decision making by patients and their doctors.

AFFILIATIONS

- ¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- ²Harvard Medical School, Boston, MA
- ³American Society of Clinical Oncology, Alexandria, VA
- ⁴The Ohio State University Comprehensive Cancer Center, Columbus, OH
- ⁵Memorial Sloan Kettering Cancer Center, New York, NY
- ⁶Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD
- ⁷US Food and Drug Administration, Silver Spring, MD
- ⁸Department of Surgery, Duke University Comprehensive Cancer Center, Durham, NC
- ⁹Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom
- ¹⁰Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
- ¹¹Gemini Group, Ann Arbor, MI
- ¹²University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
- ¹³Beth Israel Deaconess Medical Center, Boston, MA
- ¹⁴University of Colorado School of Medicine, Aurora, CO
- ¹⁵University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
- ¹⁶US Oncology Network, Virginia Cancer Specialists, Arlington, VA
- ¹⁷Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
- ¹⁸Coordinating Center for Clinical Trials, National Cancer Institute, Rockville, MD
- ¹⁹The Emmes Corporation, Rockville, MD
- ²⁰Cancer Therapy and Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD

CORRESPONDING AUTHOR

Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; e-mail: sara_tolaney@dfci.harvard.edu.

DISCLAIMER

The views expressed in this article are the authors' views and do not necessarily represent the views, opinions, or positions of ASCO, the National Cancer Institute, and the FDA.

EQUAL CONTRIBUTION

S.M.T. and E.G.-M. are co-first authors.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.20.03613>.

AUTHOR CONTRIBUTIONS

Conception and design: Sara M. Tolaney, Elizabeth Garrett-Mayer, Julia White, Victoria S. Blinder, Jared C. Foster, Laleh Amiri-Kordestani, E. Shelley Hwang, Judith M. Bliss, Jane Perlmutter, Nadine M. Tung, David Cameron, Neelima Denduluri, Angelo DiLeo, Lawrence Baizer, Lynn Pearson Butler, Eric P. Winer, Larissa A. Korde

Provision of study materials or patients: Elena Schwartz

Collection and assembly of data: Jared C. Foster, Laleh Amiri-Kordestani, E. Shelley Hwang, Eileen Rakovitch, Anthony D. Elias, David Cameron, Neelima Denduluri, Ana F. Best, Lynn Pearson Butler, Larissa A. Korde

Data analysis and interpretation: Elizabeth Garrett-Mayer, Victoria S. Blinder, Jared C. Foster, Laleh Amiri-Kordestani, E. Shelley Hwang, Judith M. Bliss, Eileen Rakovitch, Patricia A. Spears, Elizabeth Frank, Anthony D. Elias, David Cameron, Neelima Denduluri, Angelo DiLeo, Elena Schwartz, Larissa A. Korde

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

REFERENCES

1. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. *J Clin Oncol* 25:2127-2132, 2007
2. Botteri E, Veronesi P, Vila J, et al: Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery. *Br J Surg* 104:1802-1810, 2017
3. Cossetti RJ, Tyldesley SK, Speers CH, et al: Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. *J Clin Oncol* 33:65-73, 2015
4. Coleman R, Finkelstein DM, Barrios C, et al: Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol* 21:60-72, 2020
5. von Minckwitz G, Procter M, de Azambuja E, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *N Engl J Med* 377:122-131, 2017
6. von Minckwitz G, Huang CS, Mano MS, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med* 380:617-628, 2019
7. Mittendorf EA, Lu B, Melisko M, et al: Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: A randomized, multicenter, phase III clinical trial. *Clin Cancer Res* 25:4248-4254, 2019
8. Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al: NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. *J Clin Oncol* 38:444-453, 2020
9. Martin M, Holmes FA, Ejlertsen B, et al: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 18:1688-1700, 2017
10. Nitz U, Gluz O, Clemens M, et al: West German Study PlanB trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. *J Clin Oncol* 37:799-808, 2019
11. Joensuu H, Fraser J, Wildiers H, et al: Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: The SOLD randomized clinical trial. *JAMA Oncol* 4:1199-1206, 2018
12. Yardley DA, Arrowsmith ER, Daniel BR, et al: TITAN: Phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. *Breast Cancer Res Treat* 164:649-658, 2017
13. Ejlertsen B, Tuxen MK, Jakobsen EH, et al: Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. *J Clin Oncol* 35:2639-2646, 2017
14. Blum JL, Flynn PJ, Yothers G, et al: Anthracyclines in early breast cancer: The ABC trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). *J Clin Oncol* 35:2647-2655, 2017
15. Cameron D, Brown J, Dent R, et al: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. *Lancet Oncol* 14:933-942, 2013

16. Bell R, Brown J, Parmar M, et al: Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Ann Oncol* 28:754-760, 2017
17. Miller KD, O'Neill A, Gradishar W, et al: Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103). *J Clin Oncol* 36:2621-2629, 2018
18. Martín M, Barrios C, Torrecillas L, et al: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. *Cancer Res* 79, 2019 (abstr GS2-04)
19. Luch A, Barrios CH, Torrecillas L, et al: Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). *J Clin Oncol* 38:203-213, 2020
20. Shulman LN, Berry DA, Cirincione CT, et al: Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). *J Clin Oncol* 32:2311-2317, 2014
21. Margolese RG, Cecchini RS, Julian TB, et al: Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. *Lancet* 387:849-856, 2016
22. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med* 379:111-121, 2018
23. Gralow JR, Barlow WE, Paterson AHG, et al: Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. *J Natl Cancer Inst* 112: 698-707, 2020
24. Colleoni M, Gray KP, Gelber S, et al: Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group trial 22-00. *J Clin Oncol* 34:3400-3408, 2016
25. Pagani O, Regan MM, Walley BA, et al: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 371:107-118, 2014
26. Francis PA, Pagani O, Fleming GF, et al: Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N Engl J Med* 379:122-137, 2018
27. Budd GT, Barlow WE, Moore HC, et al: SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. *J Clin Oncol* 33:58-64, 2015
28. Colleoni M, Luo W, Karlsson P, et al: Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): A multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 19:127-138, 2018
29. Ruiz-Borrego M, Guerrero-Zotano A, Bermejo B, et al: Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study. *Breast Cancer Res Treat* 177:115-125, 2019
30. O'Shaughnessy J, Koeppen H, Xiao Y, et al: Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. *Clin Cancer Res* 21:4305-4311, 2015
31. Paterson AH, Anderson SJ, Lembersky BC, et al: Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. *Lancet Oncol* 13:734-742, 2012
32. Swain SM, Tang G, Geyer CE Jr, et al: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. *J Clin Oncol* 31:3197-3204, 2013
33. Martín M, Ruiz Simon A, Ruiz Borrego M, et al: Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study. *J Clin Oncol* 33:3788-3795, 2015
34. Piccart-Gebhart M, Holmes E, Baselga J, et al: Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. *J Clin Oncol* 34:1034-1042, 2016
35. Moreno-Aspitia A, McCormick Holmes E, Jackisch C, et al: Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer. *J Clin Oncol* 35, 2017 (suppl; abstr 502)
36. Krag DN, Anderson SJ, Julian TB, et al: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol* 11:927-933, 2010
37. Goss PE, Ingle JN, Pritchard KI, et al: Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—A randomized controlled phase III trial. *J Clin Oncol* 31:1398-1404, 2013
38. McCormick B, Winter K, Hudis C, et al: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. *J Clin Oncol* 33:709-715, 2015
39. Giuliano AE, Ballman KV, McCall L, et al: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. *JAMA* 318:918-926, 2017
40. Livi L, Meattini I, Marrazzo L, et al: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. *Eur J Cancer* 51:451-463, 2015
41. Fisher ER, Costantino JP, Leon ME, et al: Pathobiology of small invasive breast cancers without metastases (T1a/b, NO, MO): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21. *Cancer* 110:1929-1936, 2007
42. Kunkler IH, Williams LJ, Jack WJ, et al: Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): A randomised controlled trial. *Lancet Oncol* 16:266-273, 2015
43. Hughes KS, Schnaper LA, Berry D, et al: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. *N Engl J Med* 351:971-977, 2004
44. Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. *J Clin Oncol* 31:2382-2387, 2013
45. Solin LJ, Gray R, Hughes LL, et al: Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. *J Clin Oncol* 33:3938-3944, 2015
46. Vicini F, Cecchini R, White J, et al: Primary results of NSABP B-39/ROG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. *Cancer Res* 79, 2019 (abstr GS4-04)
47. Coles CE, Griffin CL, Kirby AM, et al: Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet* 390:1048-1060, 2017
48. Whelan TJ, Julian JA, Berrang TS, et al: External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): A randomised controlled trial. *Lancet* 394:2165-2172, 2019
49. Whelan TJ, Olivetto I, Ackerman I, et al: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. *J Clin Oncol* 29, 2011 (suppl; abstr LBA1003)

50. Mamounas EP, Bandos H, White JR, et al: NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). *J Clin Oncol* 37, 2019 (suppl; abstr TPS600)
51. Donker M, van Tienhoven G, Straver ME, et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol* 15:1303-1310, 2014
52. Clinicaltrials.gov: Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. <https://clinicaltrials.gov/ct2/show/NCT01901094>
53. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med* 373:2005-2014, 2015
54. Tolaney SM, Barry WT, Dang CT, et al: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med* 372:134-141, 2015
55. Tolaney SM, Guo H, Pernas S, et al: Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 37:1868-1875, 2019
56. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 24:3726-3734, 2006
57. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med* 375:717-729, 2016
58. Basch E, Reeve BB, Mitchell SA, et al: Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst* 106:dju244, 2014
59. US Food and Drug Administration: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, 2018. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics>
60. Fumagalli D, Bedard PL, Nahleh Z, et al: A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints. *Lancet Oncol* 13:e240-e248, 2012

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Updated Standardized Definitions for Efficacy End Points (STEPP) in Adjuvant Breast Cancer Clinical Trials: STEPP Version 2.0

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Sara M. Tolaney

Consulting or Advisory Role: Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech, Eisai, Sanofi, Celldex, Bristol Myers Squibb, Paxman, Seattle Genetics, Odonate Therapeutics, AbbVie, Silverback Therapeutics, G1 Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Immunomedics/Gilead, Mersana, Certara

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Immunomedics, Odonate Therapeutics, Sanofi, Seattle Genetics
Travel, Accommodations, Expenses: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Eisai, NanoString Technologies, Puma Biotechnology, Celldex

Elizabeth Garrett-Mayer

Consulting or Advisory Role: Deciphera, Tyme

Julia White

Research Funding: Intraop Medical

Judith M. Bliss

Research Funding: AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Pfizer, Roche, GlaxoSmithKline/Novartis, Lilly, Janssen-Cilag, Clovis Oncology
Travel, Accommodations, Expenses: Pfizer

Eileen Rakovitch

Honoraria: AstraZeneca

Research Funding: Genomic Health International

Patricia A. Spears

Consulting or Advisory Role: Pfizer

Elizabeth Frank

Honoraria: AstraZeneca

Travel, Accommodations, Expenses: Roche

Nadine M. Tung

Research Funding: AstraZeneca

Anthony D. Elias

Stock and Other Ownership Interests: AbbVie, Merck, Gilead Sciences, Allergan, Pfizer, Abbott Laboratories, Amgen, Bristol Myers Squibb, United

Health Group, Align Oncology, Illumina, Exact Sciences, Lilly, Agilent, Cigna, Alexion Pharmaceuticals, Biogenex

Consulting or Advisory Role: Ayala Pharmaceuticals

Research Funding: Medivation, Astellas Pharma, Genentech, Deciphera, Xencor, Infinity Pharmaceuticals, Karyopharm Therapeutics, TopAlliance BioSciences Inc, Fosun Urinove, BioAtla
Uncompensated Relationships: Seiyax

David Cameron

Consulting or Advisory Role: Lilly, Novartis, Research Triangle Institute Health Solutions, Daiichi Sankyo, Prima BioMed, Merck Sharp & Dohme, Zymeworks, Eisai, Puma Biotechnology, Pfizer, Oncolytics, Roche, Samsung Bioepis, Seattle Genetics, Synthon, Clarity Pharmaceuticals

Research Funding: Roche, Novartis, AstraZeneca

Travel, Accommodations, Expenses: Novartis

Neelima Denduluri

Employment: AstraZeneca

Research Funding: Amgen, Novartis, Genentech, Lilly, Pfizer, Daiichi Sankyo, Immunomedics

Travel, Accommodations, Expenses: Seattle Genetics

Angelo DiLeo

Honoraria: Roche, Novartis, Pfizer, AstraZeneca, Eisai, Lilly, Celgene, Amgen

Consulting or Advisory Role: Roche, Novartis, Pfizer, AstraZeneca, Lilly, Celgene, Puma Biotechnology, Ipsen, Genentech, Amgen, Seattle Genetics, Genomic Health, Athenex, Daiichi Sankyo

Travel, Accommodations, Expenses: Roche, Pfizer, Celgene, Novartis

Eric P. Winer

Honoraria: Genentech/Roche, Genomic Health

Consulting or Advisory Role: Leap Therapeutics, Seattle Genetics, Jounce Therapeutics, GlaxoSmithKline, Carrick Therapeutics, Lilly, G1 Therapeutics, Syros Pharmaceuticals, Genentech/Roche, Gilead Sciences, Zymeworks

Research Funding: Genentech, AstraZeneca

Other Relationship: InfiniteMD

No other potential conflicts of interest were reported.